Neurizon Therapeutics Ltd: Appendix 4C & Quarterly Update
Neurizon Therapeutics Ltd: Notice of Quarterly Shareholder Update Webinar
Neurizon Therapeutics Ltd: Appointment of Chief Financial Officer
Neurizon Therapeutics Ltd: Leadership team strengthened with strategic appointments
Neurizon Therapeutics Ltd: NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells
Neurizon Therapeutics Ltd: NUZ-001 Shows Positive Results in Human 3D Brain Model
Neurizon Therapeutics Ltd: NUZ-001 shows promising respiratory outcome
Neurizon Therapeutics Ltd: Neurizon Commences Initiatives to Lift Clinical Hold
Neurizon Therapeutics Ltd: Appendix 4D - Half-year Financial Report - 31 December 2024
Neurizon Therapeutics Ltd: Neurizon to Present Latest Results and Key Updates
Neurizon Therapeutics Ltd: FDA Guidance on NUZ-001 IND Application
Neurizon Therapeutics Ltd: Notice of Company Update Webinar
Neurizon Therapeutics Ltd: Change of Director's Interest Notices x3
Neurizon Therapeutics Ltd: US Patent granted for NUZ-001
Neurizon Therapeutics Ltd: Notification regarding unquoted securities - NUZ
Neurizon Therapeutics Ltd: Appendix 4C & Quarterly Update
Neurizon Therapeutics Ltd: Neurizon updates on NUZ-001 IND Application
Neurizon Therapeutics Ltd: Change of Share Registry
Neurizon Therapeutics Ltd: Section 708A Cleansing Statement
Neurizon Therapeutics Ltd: Application for quotation of securities - NUZ